Elovie (bevacizumab biosimilar) for metastatic colorectal cancer in Brazil

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, multicenter study will collect real-world clinical data from specialized cancer centers in Brazil on adults with unresectable stage IV metastatic colorectal cancer treated with Elovie. Patients will receive standard care determined by their treating physicians and data on effectiveness, safety, demographics, and treatment patterns will be extracted into a study-specific case report form. Eligible participants include adults who started first-line treatment with Elovie or who switched to Elovie and completed at least one cycle, with their records available at participating sites. No experimental interventions are administered and follow-up reflects routine clinical practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants of both sexes aged 18 years or older at the start of treatment with bevacizumab;
* Participants diagnosed with metastatic colorectal cancer, clinical stage IV, unresectable, by clinical definition in medical records, according to the investigator's assessment at the initial consultation and before any type of palliative treatment;
* Participants who are undergoing first-line treatment with Elovie and who have completed at least 1 cycle of treatment or participants who have started first-line treatment with another bevacizumab (reference or another biosimilar other than Elovie) but who have currently switched to Elovie and completed at least 1 cycle of treatment with it, and whose data is available at the institution participating in the study;
* Participants with the capacity to understand and consent to their participation in the study through the Free and Informed Consent Form

Exclusion Criteria:

* Participants who use or have used bevacizumab in a manner different from that described in the current version of the Elovie® package insert;
* Participants who have been treated with Elovie for a period longer than 12 treatment cycles;
* Participants who have started first-line treatment with another bevacizumab (reference or another biosimilar other than Elovie) and have completed more than 2 treatment cycles with it;
* Participants with a concomitant diagnosis of another active malignant neoplasm other than metastatic colorectal cancer.

Where it's running

• Unimed Vitória
  Vitória, Espírito Santo, Brazil Recruiting
• Centro de Oncologia do Paraná (COP)
  Curitiba, Paraná, Brazil Recruiting
• Centro de Pesquisa Unimed Londrina
  Londrina, Paraná, Brazil Recruiting
• Instituto Dor de Pesquisa E Ensino
  Recife, Pernambuco, Brazil Recruiting
• Centro de Ensino e Pesquisa - Hospital São Marcos
  Teresina, Piauí, Brazil Recruiting
• Centro de Pesquisa Unimed Porto Alegre
  Porto Alegre, Rio Grande do Sul, Brazil Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Second-line combination treatment for MSS metastatic colorectal cancer

  This trial will try folinic acid plus continuous 5-FU with liposomal irinotecan, sometimes combined with cetuximab or bevacizumab, as a second-line option for adults with MSS metastatic colorectal cancer who progressed on or cannot tolerate oxaliplatin-based therapy.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07559760

• Comparing Precem-TcT (with or without bevacizumab) versus trifluridine/tipiracil plus bevacizumab for people with previously treated metastatic colorectal cancer

  This trial will see if Precem-TcT, alone or with bevacizumab, helps people with metastatic colorectal cancer who have already received standard chemotherapy, compared with trifluridine/tipiracil plus bevacizumab.

  Recruiting at 116 sites Phase 3 EMD Serono · San Francisco, California and 115 other locations · NCT07549412

• Evaluating a new treatment for metastatic colorectal cancer

  This study is testing a new drug combined with standard chemotherapy to see if it helps adults with metastatic colorectal cancer feel better and improve their condition.

  Recruiting at 82 sites Phase 2 AbbVie · Duarte, California and 81 other locations · NCT06820463

• Combining radioembolization with FTD-TPI and bevacizumab for advanced colorectal cancer

  This study is testing if a new combination of a targeted radiation treatment and two medications can help people with advanced colorectal cancer who haven't responded to other treatments.

  Recruiting Phase 2 UMC Utrecht · Utrecht · NCT06563986

• Combination therapy for metastatic colorectal cancer with BRAF-V600E mutation

  This study is testing a new combination of three drugs to see if it can help people with advanced colorectal cancer that has a specific mutation feel better and live longer after their previous treatments stopped working.

  Recruiting Phase 2 Vall d'Hebron Institute of Oncology · Barcelona · NCT06411600

• Using irinotecan liposomes with chemotherapy for advanced colorectal cancer

  This study is testing if a new way of giving irinotecan with chemotherapy can help people with advanced colorectal cancer live longer and feel better.

  Recruiting Phase 2 West China Hospital · Sichuan, Sichuan, Chengdu · NCT06341296

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.